BIONTECH (Brazil) Today
| B1NT34 Stock | BRL 34.00 1.01 2.88% |
PerformanceVery Weak
| Odds Of DistressLow
|
BIONTECH is trading at 34.00 as of the 21st of March 2025, a 2.88% down since the beginning of the trading day. The stock's open price was 35.01. BIONTECH has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Moving together with BIONTECH Stock
Moving against BIONTECH Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
BIONTECH Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BIONTECH's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BIONTECH or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Idea | IT (View all Themes) |
| Business Concentration | IT, Biotechnology, Healthcare, Computing (View all Sectors) |
BIONTECH SE DRN (B1NT34) is traded on Sao Paulo Exchange in Brazil and employs 4,000 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 184.35 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BIONTECH's market, we take the total number of its shares issued and multiply it by BIONTECH's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BIONTECH SE DRN operates under Healthcare sector and is part of Biotechnology industry. The entity has 3.88 B outstanding shares.
BIONTECH generates positive cash flow from operations, but has no cash available
Check BIONTECH Probability Of Bankruptcy
BIONTECH SE DRN Risk Profiles
Although BIONTECH's alpha and beta are two of the key measurements used to evaluate BIONTECH's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.12 | |||
| Standard Deviation | 2.73 | |||
| Variance | 7.47 | |||
| Risk Adjusted Performance | (0.10) |
BIONTECH Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in BIONTECH without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Volatility Analysis Now
Volatility AnalysisGet historical volatility and risk analysis based on latest market data |
| All Next | Launch Module |
BIONTECH Corporate Management
Elected by the shareholders, the BIONTECH's board of directors comprises two types of representatives: BIONTECH inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BIONTECH. The board's role is to monitor BIONTECH's management team and ensure that shareholders' interests are well served. BIONTECH's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BIONTECH's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jens Holstein | CFO Board | Profile | |
| Sylke Maas | VP Strategy | Profile | |
| James Ryan | Sr Counsel | Profile | |
| Michael Boehler | MD Communications | Profile | |
| Ryan Richardson | MD Officer | Profile | |
| Sierk Poetting | COO MD | Profile |
Other Information on Investing in BIONTECH Stock
BIONTECH financial ratios help investors to determine whether BIONTECH Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BIONTECH with respect to the benefits of owning BIONTECH security.